New JAMA Study Showcases Clinical Benefits of SleepioRx in Patients with Comorbid Insomnia and Depression Symptoms, Marking 100+ Peer-Reviewed Papers for Big Health
Big Health has reached a major milestone during Sleep Awareness Week: the publication of over 100 peer-reviewed papers that validate our digital solutions and methods for treating insomnia and other common mental health conditions.
This milestone underscores our ongoing commitment to providing accessible, evidence-based mental health solutions for the millions who need support. We’re proud to advance the science of sleep and mental health, and we’re excited to see the impact these findings will have on patients and clinical practice.
The latest paper (link here), published by Journal of the American Medical Association (JAMA), investigates the use of SleepioRx, an FDA-cleared digital insomnia treatment based on guideline-recommended cognitive behavioral therapy for insomnia (CBT-I), on patients who have both chronic insomnia and depression.
The blinded randomized controlled trial, led by researchers at Oxford University, investigated whether digital cognitive behavioral therapy for insomnia modifies negative bias in the perception of emotional facial expressions and whether that in turn leads to improvement in depressive symptoms.
205 participants were followed over ten weeks after being randomly assigned to SleepioRx or Sleep Hygiene Education, a component of standard of care treatment for insomnia.
The study builds on the larger body of evidence confirming that SleepioRx is an effective treatment for insomnia, showing large treatment effects in insomnia symptoms as measured on the Insomnia Severity Index (ISI), when compared to the control arm.
Of interest, the study showed that use of SleepioRx also led to large treatment effects on depression symptoms as measured on the Patient Health Questionnaire (PHQ-9), compared to the control arm.
We are excited to see further research expand on this work.
____________________________
SleepioRx is a digital therapeutic intended for the treatment of chronic insomnia / insomnia disorder as an adjunct to usual care in patients aged 18 and older. SleepioRx is a prescription device delivering Cognitive Behavioral Therapy for Insomnia (CBT-I) and can be made available on the order of a licensed healthcare provider.
Sleepio is not intended for treatment of depression, and has not been reviewed or cleared by FDA for this purpose.
DOC-3838 Effective March 2025
